Up-regulation of apoptosis and regeneration genes in the dorsal root ganglia during cisplatin treatment

Experimental Neurology

Volumn 210, Issue 2, 2008, Pages 368-374

  Alaedini, Armin ^a   Xiang, Zhaoying ^b   Kim, Hesed ^b   Sung, Ying Ju ^c   Latov, Norman ^a  

^a Department of Obstetrics Gynecology   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Apoptosis; Bid3; Cancer; Cisplatin; Gene expression analysis; Mmp9; Neuropathy; Neuroregeneration; Neurotoxicity; p21

Indexed keywords

CALGRANULIN A; CALGRANULIN B; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BID3 GENE; CD163 GENE; CDKN1A GENE; CELL REGENERATION; CKAP2 GENE; CONTROLLED STUDY; DRUG EFFICACY; FABP7 GENE; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GFAP GENE; MMP9 GENE; NEUROPATHY; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL NERVE; PRIORITY JOURNAL; RAT; S100A8 GENE; S100A9 GENE; SPINAL GANGLION;

ANIMALS; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CISPLATIN; GANGLIA, SPINAL; MALE; MICROARRAY ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; UP-REGULATION;

EID: 41149162713     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.11.018     Document Type: Article

References (42)

1. Albers J., Chaudhry V., Cavaletti G., and Donehower R. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev (2007) CD005228
2. Asada M., Yamada T., Ichijo H., Delia D., Miyazono K., Fukumuro K., and Mizutani S. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 18 (1999) 1223-1234
3. Authier N., Gillet J.P., Fialip J., Eschalier A., and Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp. Neurol. 182 (2003) 12-20
4. Bianchi R., Gilardini A., Rodriguez-Menendez V., Oggioni N., Canta A., Colombo T., De Michele G., Martone S., Sfacteria A., Piedemonte G., Grasso G., Beccaglia P., Ghezzi P., D'Incalci M., Lauria G., and Cavaletti G. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur. J. Cancer 43 (2007) 710-717
5. Costanzo R.M., Perrino L.A., and Kobayashi M. Response of matrix metalloproteinase-9 to olfactory nerve injury. NeuroReport 17 (2006) 1787-1791
6. Coultas L., Terzano S., Thomas T., Voss A., Reid K., Stanley E.G., Scott C.L., Bouillet P., Bartlett P., Ham J., Adams J.M., and Strasser A. Hrk/DP5 contributes to the apoptosis of select neuronal populations but is dispensable for haematopoietic cell apoptosis. J. Cell Sci. 120 (2007) 2044-2052
7. Dubois B., Masure S., Hurtenbach U., Paemen L., Heremans H., van den Oord J., Sciot R., Meinhardt T., Hammerling G., Opdenakker G., and Arnold B. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J. Clin. Invest. 104 (1999) 1507-1515
8. Eberwine J. Amplification of mRNA populations using aRNA generated from immobilized oligo(dT)-T7 primed cDNA. BioTechniques 20 (1996) 584-591
9. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
10. Eng L.F., Ghirnikar R.S., and Lee Y.L. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem. Res. 25 (2000) 1439-1451
11. Gartel A.L., and Radhakrishnan S.K. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 65 (2005) 3980-3985
12. Godbout R., Bisgrove D.A., Shkolny D., and Day III R.S. Correlation of B-FABP and GFAP expression in malignant glioma. Oncogene 16 (1998) 1955-1962
13. Gurer G., Erdem S., Kocaefe C., Ozguc M., and Tan E. Expression of matrix metalloproteinases in vasculitic neuropathy. Rheumatol. Int. 24 (2004) 255-259
14. Imaizumi K., Benito A., Kiryu-Seo S., Gonzalez V., Inohara N., Lieberman A.P., Kiyama H., and Nunez G. Critical role for DP5/Harakiri, a Bcl-2 homology domain 3-only Bcl-2 family member, in axotomy-induced neuronal cell death. J. Neurosci. 24 (2004) 3721-3725
15. Inohara N., Ding L., Chen S., and Nunez G. Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J. 16 (1997) 1686-1694
16. Jamieson E.R., and Lippard S.J. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem. Rev. 99 (1999) 2467-2498
17. Jann S., Bramerio M.A., Beretta S., Koch S., Defanti C.A., Toyka K.V., and Sommer C. Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP. Neurology 61 (2003) 1607-1610
18. Kiaei M., Kipiani K., Calingasan N.Y., Wille E., Chen J., Heissig B., Rafii S., Lorenzl S., and Beal M.F. Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 205 (2007) 74-81
19. Krueger S.K., and Williams D.E. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol. Ther. 106 (2005) 357-387
20. Kumral A., Genc S., Ozer E., Yilmaz O., Gokmen N., Koroglu T.F., Duman N., Genc K., and Ozkan H. Erythropoietin downregulates bax and DP5 proapoptotic gene expression in neonatal hypoxic-ischemic brain injury. Biol. Neonate 89 (2006) 205-210
21. Larsen P.H., DaSilva A.G., Conant K., and Yong V.W. Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and-12 null mice. J. Neurosci. 26 (2006) 2207-2214
22. Lauria G., Lombardi R., Borgna M., Penza P., Bianchi R., Savino C., Canta A., Nicolini G., Marmiroli P., and Cavaletti G. Intraepidermal nerve fiber density in rat foot pad: neuropathologic-neurophysiologic correlation. J. Peripher. Nerv. Syst. 10 (2005) 202-208
23. Leibel R.L., Chung W.K., and Chua Jr. S.C. The molecular genetics of rodent single gene obesities. J. Biol. Chem. 272 (1997) 31937-31940
24. Leppert D., Hughes P., Huber S., Erne B., Grygar C., Said G., Miller K.M., Steck A.J., Probst A., and Fuhr P. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Neurology 53 (1999) 62-70
25. Megyesi J., Safirstein R.L., and Price P.M. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J. Clin. Invest. 101 (1998) 777-782
26. Menet V., Gimenez Y.R.M., Sandillon F., and Privat A. GFAP null astrocytes are a favorable substrate for neuronal survival and neurite growth. Glia 31 (2000) 267-272
27. Miyaji T., Kato A., Yasuda H., Fujigaki Y., and Hishida A. Role of the increase in p21 in cisplatin-induced acute renal failure in rats. J. Am. Soc. Nephrol. 12 (2001) 900-908
28. Nath K.A. Provenance of the protective property of p21. Am. J. Physiol., Renal Physiol. 289 (2005) F512-F513
29. Price P.M., Megyesi J., and Safirstein R.L. Cell cycle regulation: repair and regeneration in acute renal failure. Semin. Nephrol. 23 (2003) 449-459
30. Price P.M., Safirstein R.L., and Megyesi J. Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am. J. Physiol., Renal Physiol. 286 (2004) F378-F384
31. Price P.M., Yu F., Kaldis P., Aleem E., Nowak G., Safirstein R.L., and Megyesi J. Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2. J. Am. Soc. Nephrol. 17 (2006) 2434-2442
32. Quasthoff S., and Hartung H.P. Chemotherapy-induced peripheral neuropathy. J. Neurol. 249 (2002) 9-17
33. Romanic A.M., White R.F., Arleth A.J., Ohlstein E.H., and Barone F.C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29 (1998) 1020-1030
34. Shubayev V.I., and Myers R.R. Endoneurial remodeling by TNFalph-and TNFalpha-releasing proteases. A spatial and temporal co-localization study in painful neuropathy. J. Peripher. Nerv. Syst. 7 (2002) 28-36
35. Shubayev V.I., and Myers R.R. Matrix metalloproteinase-9 promotes nerve growth factor-induced neurite elongation but not new sprout formation in vitro. J. Neurosci. Res. 77 (2004) 229-239
36. Ta L.E., Espeset L., Podratz J., and Windebank A.J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27 (2006) 992-1002
37. Umapathi T., and Chaudhry V. Toxic neuropathy. Curr. Opin. Neurol. 18 (2005) 574-580
38. Van Gelder R.N., von Zastrow M.E., Yool A., Dement W.C., Barchas J.D., and Eberwine J.H. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 1663-1667
39. Wang D., and Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev., Drug Discov. 4 (2005) 307-320
40. Yong V.W., Power C., Forsyth P., and Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. 2 (2001) 502-511
41. Yu F., Megyesi J., Safirstein R.L., and Price P.M. Identification of the functional domain of p21(WAF1/CIP1) that protects cells from cisplatin cytotoxicity. Am. J. Physiol., Renal Physiol. 289 (2005) F514-F520
42. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., and Hung M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3 (2001) 245-252